EVALUATION AND COMPARISON OF CYTOTOXIC EFFECT OF VILAZODONE HYDROCHLORIDE WITH 5-FLUOROURACIL IN HT-29 BOWEL CANCER CELL LINE
Objectives: Vilazodone hydrochloride is a novel selective serotonin reuptake inhibitor (SSRI) used to treat major depressive disorders. There are only sparse data available to know about the SSRI’s and its association with colon cancer. This study aims to evaluate and compare the in vitro cytotoxic effect of vilazodone with 5-fluorouracil (5-FU) in HT-29 cell line.
Methods: Cell viability was tested by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Mosmann, 1983). Test sample and standard drug in variable concentrations were added to the HT-29 cell lines for incubation over 24 h under ideal conditions. After washing the test and standard drug sample from the well with saline, MTT was added and incubated for 4 h. Dimethyl sulfoxide of 1 ml was added in all wells after incubation with MTT. The absorbance at 570 nm was measured with an ultraviolet - spectrophotometer.
Results: The values were tabulated, and the graph was plotted to find the IC-50 value (inhibitory concentration at 50%) which was struck at 28.5 μg/ml and12. 8 μg/ml for vilazodone hydrochloride and 5-FU, respectively.
Conclusion: The results show that vilazodone hydrochloride has good anticancer property comparable with 5-FU, which would probably play a role as a cytotoxic agent in tumor cells. The proposed mechanism of action could be by activation of caspase-3 enzyme, thereby increasing apoptosis and indicates its use in coexisting depression and colon carcinoma. Other mechanism includes suppression of oncogene p53, which can be confirmed by future studies.
2. Hamedjwied TA, Nadan A, Mohammed MA. Evaluation of chemo preventive response of pentoxiphylline and sildenafil in colorectal carcinoma experimentally induced in rats: Comparative study with 5-fluorouracil. Int J Pharm Pharm Sci 2015;7 S l:217-22.
3. Bielecka AM, Obuchowicz E. Antidepressant drugs as a complementary therapeutic strategy in cancer. Exp Biol Med (Maywood) 2013;238:849-58.
4. Kumar MV, Priyanka PS, Prashanth P, Jyothirmai P. Association of patient related risk factors with the effectiveness of palliative chemotherapy in cancer patients. Int J Pharm Pharm Sci 2017;9 :.
5. Sternbach H. Are antidepressants carcinogenic? A review of preclinical and clinical studies. J Clin Psychiatry 2003;64:1153-62.
6. Kirkova M, Tzvetanova E, Vircheva S, Zamfirova R, Grygier B, Kubera M, et al. Antioxidant activity of fluoxetine: Studies in mice melanoma model. Cell Biochem Funct 2010;28:497-502.
7. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like burkitt lymphoma cells. Blood 2003;101:3212-9.
8. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines. J Mol Biol 2005;27:29-42.
9. Cosgrove L, Shi L, Creasey DE, Anaya-McKivergan M, Myers JA, Huybrechts KF, et al. Antidepressants and breast and ovarian cancer risk: A review of the literature and researchers’ financial associations with industry. PLoS One 2011;6:e18210.
10. Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151:951-7.
11. Sharpe CR, Collet JP, Belzile E, Hanley JA, Boivin JF. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002;86:92-7.
12. Freire-Garabal M, Núñez MJ, Pereiro D, Riveiro P, Losada C, Fernández-Rial J, et al. Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 1998;63:PL31-8.
13. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU, et al. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract 2013;17:160-9.
14. Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, et al. Vilazodone: Clinical basis for the US food and drug administration’s approval of a new antidepressant. J Clin Psychiatry 2011;72:1166-73.
15. Cruz MP. Vilazodone HCl (viibryd): A serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. J Clin Pharm Ther 2012;37:28.
16. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: The MTT assay. Methods Mol Biol 2011;731:237-45.
17. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
18. Xu W, Tamim H, Shapiro S, Stang MR, Collet JP. Use of antidepressants and risk of colorectal cancer: A nested case-control study. Lancet Oncol 2006;7:301-8.
19. Reddy KK, Lefkove B, Chen LB, Govindarajan B, Carracedo A, Velasco G, et al. The antidepressant sertraline down regulates akt and has activity against melanoma cells. Pigment Cell Melanoma Res 2008;21:451-6.
20. Torricelli C, Salvadori S, Valacchi G, Sou?ek K, Slabáková E, Muscettola M, et al. Alternative pathways of cancer cell death by rottlerin: Apoptosis versus autophagy. Evid Based Complement Alternat Med 2012;2012:980658.
21. Abdel-Razaq W, Kendall DA, Bates TE. The effects of antidepressants on mitochondrial function in a model cell system and isolated mitochondria. Neurochem Res 2011;36:327-38.
22. Krishnan A, Hariharan R, Nair SA, Pillai MR. Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol 2008;75:1924-34.
23. Stepulak A, Rzeski W, Sifringer M, Brocke K, Gratopp A, Kupisz K, et al. Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther 2008;7:1685-93.
24. Cloonan SM, Williams DC. The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt’s lymphoma. Int J Cancer 2011;128:1712-23.
25. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-?/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206.
26. Koh SJ, Kim JM, Kim IK, Kim N, Jung HC, Song IS, et al. Fluoxetine inhibits NF-?B signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol 2011;301:G9-19.
27. Lee CS, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol 2010;106:446-53.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.